Oncotelic Therapeutics Inc (OTLC)
0.0371
0.00 (0.00%)
USD |
OTCM |
May 31, 16:00
Oncotelic Therapeutics Enterprise Value: 26.95M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 26.95M |
| May 30, 2024 | 27.71M |
| May 29, 2024 | 26.91M |
| May 28, 2024 | 27.31M |
| May 24, 2024 | 26.91M |
| May 23, 2024 | 26.51M |
| May 22, 2024 | 26.75M |
| May 21, 2024 | 27.20M |
| May 20, 2024 | 27.63M |
| May 17, 2024 | 27.31M |
| May 16, 2024 | 27.11M |
| May 15, 2024 | 26.51M |
| May 14, 2024 | 27.71M |
| May 13, 2024 | 27.53M |
| May 10, 2024 | 27.41M |
| May 09, 2024 | 27.61M |
| May 08, 2024 | 27.87M |
| May 07, 2024 | 27.15M |
| May 06, 2024 | 27.31M |
| May 03, 2024 | 27.87M |
| May 02, 2024 | 27.44M |
| May 01, 2024 | 27.63M |
| April 30, 2024 | 28.09M |
| April 29, 2024 | 28.91M |
| April 26, 2024 | 28.91M |
| Date | Value |
|---|---|
| April 25, 2024 | 28.43M |
| April 24, 2024 | 27.31M |
| April 23, 2024 | 26.51M |
| April 22, 2024 | 27.87M |
| April 19, 2024 | 27.87M |
| April 18, 2024 | 28.91M |
| April 17, 2024 | 28.47M |
| April 16, 2024 | 28.55M |
| April 15, 2024 | 28.55M |
| April 12, 2024 | 28.51M |
| April 11, 2024 | 28.51M |
| April 10, 2024 | 28.51M |
| April 09, 2024 | 28.73M |
| April 08, 2024 | 28.91M |
| April 05, 2024 | 28.51M |
| April 04, 2024 | 26.96M |
| April 03, 2024 | 26.32M |
| April 02, 2024 | 26.22M |
| April 01, 2024 | 27.67M |
| March 28, 2024 | 26.25M |
| March 27, 2024 | 26.26M |
| March 26, 2024 | 27.65M |
| March 25, 2024 | 26.51M |
| March 22, 2024 | 26.51M |
| March 21, 2024 | 26.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
8.448M
Minimum
Mar 16 2020
138.45M
Maximum
Mar 31 2021
38.95M
Average
27.59M
Median
Enterprise Value Benchmarks
| Mosaic ImmunoEngineering Inc | 4.314M |
| NovaBay Pharmaceuticals Inc | 4.387M |
| Palatin Technologies Inc | 19.03M |
| iBio Inc | 28.91M |
| Theriva Biologics Inc | -10.98M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.4087M |
| Total Expenses (Quarterly) | 0.1672M |
| EPS Diluted (Quarterly) | -0.001 |
| Earnings Yield | -55.88% |
| Normalized Earnings Yield | -48.91 |